Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Cytomegalovirus Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 12 articles: HTML format Text format

Single Articles

January 2019
1. TURNER N, Strand A, Grewal DS, Cox G, et al
   Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series.
   Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.02337.
   PubMed     Text format     Abstract available
   
   
   October 2018
2. WANG Y, Mukhopadhyay R, Roy S, Kapoor A, et al
   Inhibition of Cytomegalovirus Replication with Extended Half-Life Synthetic Ozonides.
   Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01735.
   PubMed     Text format     Abstract available
   
   
   June 2018
3. CHOU S, Satterwhite LE, Ercolani RJ
   A New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by in vitro Exposure to Letermovir and Ganciclovir.
   Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00922.
   PubMed     Text format     Abstract available
   
   
   April 2018
4. OIKNINE-DJIAN E, Weisblum Y, Panet A, Wong HN, et al
   The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.
   Antimicrob Agents Chemother. 2018 Apr 30. pii: AAC.00288.
   PubMed     Text format     Abstract available
   
   
   March 2018
5. DONG Q, Leroux S, Shi HY, Xu HY, et al
   Model-based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection: A Pilot Study.
   Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.00075.
   PubMed     Text format     Abstract available
   
   
   November 2017
6. DENG R, Wang Y, Maia M, Burgess T, et al
   Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anti-cytomegalovirus monoclonal antibodies, in a Phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients.
   Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01108.
   PubMed     Text format     Abstract available
   
   
   October 2017
7. MENG W, Tang A, Ye X, Gui X, et al
   Targeting Human Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-gB Bispecific Antibody.
   Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01719.
   PubMed     Text format     Abstract available
   
   
   August 2017
8. CHOU S
   Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
   Antimicrob Agents Chemother. 2017 Aug 21. pii: AAC.01325.
   PubMed     Text format     Abstract available
   
   
   
9. PIRET J, Goyette N, Boivin G
   Drug Susceptibility and Replicative Capacity of Multi-Drug Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes.
   Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01044.
   PubMed     Text format     Abstract available
   
   
   November 2016
10. ISHIDA JH, Patel A, Mehta AK, Gatault P, et al
    Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01794.
    PubMed     Text format     Abstract available
    
    
    April 2016
11. PADULLES A, Colom H, Bestard O, Melilli E, et al
    Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
    Antimicrob Agents Chemother. 2016;60:1992-2002.
    PubMed     Text format     Abstract available
    
    
    November 2015
12. VAZQUEZ JA, Manavathu EK
    Molecular Characterization of a Voriconazole-resistant, Posaconazole-susceptible, Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States.
    Antimicrob Agents Chemother. 2015 Nov 16. pii: AAC.01130.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cytomegalovirus Infection is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: